The Access Problem Ketamine Still Can't Shake
Ketamine has emerged as one of the most promising interventions for treatment-resistant depression in a generation. Clinics are open in most major U.S. cities, outcomes data continues to build, and demand from patients who have exhausted other options is high. Yet in 2026, most private insurers still refuse to cover infusion-based ketamine therapy — leaving patients to shoulder costs that routinely run $400 to $800 per session, with a standard initial series of six sessions. For many, that math is simply impossible.
A new report from The Daily Northwestern highlights one organization working to bridge that gap: a Chicago-area foundation that is directly funding ketamine treatment for patients who cannot afford to wait for the insurance system to catch up. While the piece focuses on a local effort, it points to a much larger national pattern — and raises important questions about how the ketamine field handles equity as it matures.
Why Insurers Are Still Sitting This Out
The insurance coverage landscape for ketamine is complicated, and it's worth understanding why. The FDA has approved esketamine nasal spray (Spravato) for treatment-resistant depression and major depressive disorder with suicidal ideation — and Spravato does carry insurance coverage pathways, including through Medicare and some commercial plans, though prior authorization requirements are often burdensome. IV ketamine infusions, however, are a different story. Because IV ketamine is used off-label for depression — meaning the FDA approved the drug itself, but not specifically this route and indication — insurers have broad latitude to decline coverage, and most do.
This creates a two-tier system. Patients with access to funds, or those who happen to land with a provider who offers sliding-scale fees, can pursue IV infusions. Everyone else either settles for oral or intranasal options (which have a different evidence base and pharmacokinetic profile), waits for Spravato authorization, or goes without. The Chicago foundation described in the Northwestern article is trying to occupy that gap for patients in acute need — particularly those dealing with severe or suicidal depression who cannot wait months for an insurance decision.
Philanthropy as a Stop-Gap: What It Signals
It's meaningful that private philanthropic dollars are flowing into ketamine access. It signals that the clinical case for ketamine is now strong enough that funders — who are typically risk-averse — are willing to put their names and money behind it. It also signals something less optimistic: that the mainstream healthcare financing system has not kept pace with clinical reality. When foundations have to step in to fund a treatment that has been in active clinical use for depression for well over a decade, that's a structural failure, not an edge case.
This dynamic is not unique to ketamine. Psychedelic-adjacent therapies broadly face the same insurance limbo — treatments that show strong outcomes in clinical populations but remain outside standard coverage because they don't fit neatly into existing billing and prior authorization frameworks. For ketamine specifically, the off-label designation has been the primary barrier, and there is no clear federal or industry timeline for resolving it.
What Patients Should Know Right Now
If cost is a barrier to ketamine treatment, there are a few concrete avenues worth exploring before assuming the door is closed entirely. First, Spravato (esketamine) is the only FDA-approved ketamine-derived therapy for depression with a formal insurance pathway — if you haven't explored whether you qualify and whether your plan covers it, that's a logical first step. Second, an increasing number of ketamine clinics offer income-based pricing, payment plans, or maintain relationships with assistance programs; it's worth asking directly rather than assuming standard pricing is the only option. Third, nonprofit and foundation-based assistance programs like the one described in this story do exist, though they are not always easy to find — patient advocacy organizations focused on depression and mental health can sometimes point toward them.
For patients weighing IV ketamine versus Spravato, the choice isn't purely financial — the two have meaningfully different delivery mechanisms, clinical settings, and evidence profiles — but cost and coverage should be part of an honest conversation with any provider you're evaluating.
Key Takeaway
Most insurers still don't cover IV ketamine infusions for depression in 2026. If cost is a barrier, ask providers directly about assistance programs, compare Spravato's insurance pathway as an alternative, and look into nonprofit funding sources — they exist, even if they're not widely advertised. The system hasn't caught up to the evidence; that doesn't mean your options are exhausted.
The Bigger Picture
Stories like this one matter beyond the local interest angle. Every time a foundation steps in to fund treatment that insurance should be covering, it documents — publicly — that the gap is real and that the clinical case is strong enough to attract philanthropic confidence. That documentation, over time, becomes part of the evidentiary and advocacy record that pushes payers to reconsider their coverage policies. It's a slow process. But the accumulation of these efforts — in Chicago and elsewhere — is part of how access eventually expands. The original reporting from The Daily Northwestern is available here.
Share